Bloomberg Law’s combination of innovative analytics, research tools and practical guidance provides you with everything you need to be a successful litigator.
By Peter Hayes
June 2 — Pfizer Inc. isn't liable as an “apparent manufacturer” of Insulag, an asbestos-containing cement made by a company it acquired, the Maryland Court of Special Appeals ruled ( Stein v. Pfizer Inc., 2016 BL 171782, Md. Ct. Spec. App., No. 1231/14, 5/31/16 ).
The estate of a worker who died of mesothelioma can't pursue a product liability suit against Pfizer, but is instead limited to claims in a bankruptcy trust in the Southern District of New York, the court said.
Quigley Inc. manufactured and sold Insulag to Bethlehem Steel Corp. before and after Quigley became a wholly-owned subsidiary of Pfizer.
Carl Stein worked at Bethlehem Steel, where he was allegedly exposed to asbestos.
Stein's estate sued Pfizer, alleging it was an “apparent manufacturer” of Insulag.
The estate alleged that Pfizer, by placing its logo on Insulag packaging and on advertisements, “held itself out to consumers as a manufacturer of Insulag.”
Under the objective test applied by most states, the court said the claim fails because Bethlehem Steel knew, at all relevant times, that it was purchasing Insulag from Quigley, not Pfizer.
Under the actual reliance test, Stein's failure to mention Insulag or Pfizer in his deposition testimony shows no reliance by the user, the court said.
“Nor was any evidence adduced that Bethlehem Steel actually relied upon Pfizer's trademark, reputation, or assurances of quality, in deciding to purchase Insulag,” the court said.
Judge Peter B. Krauser wrote the opinion, joined by Judges Kathryn Grill Graeff and Christopher B. Kehoe.
Law Offices of Peter G. Angelos P.C. in Baltimore represented the estate of Carl Stein.
Skadden, Arps, Slate, Meagher & Flom LLP in New York represents Pfizer.
To contact the reporter on this story: Peter Hayes at email@example.com
Full text of the opinion available at http://www.bloomberglaw.com/public/document/Stein_v_Pfizer_Inc_No_1231_2016_BL_171782_Md_Ct_Spec_App_May_31_2.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)